Purpose To assess the pathological and the oncologic outcomes of the prostate cancer (PCa) missed by 6-and 12-core biopsy protocols by using a reference 21-core scheme. Between 2001 and 2009, all patients who had PCa detected in an initial 21-core TRUS biopsy scheme and were treated by a radical prostatectomy (RP) were included. Patients were sorted in 3 groups according to the diagnosis site: sextant (6 Wrst cores; group 1), peripheral zone (12 Wrst cores; group 2) or midline/transitional zone (after 21 cores; group 3). Demographics, pathological features in biopsy and RP specimens and follow-up after RP were analyzed. The 5-year progressionfree survival (PFS) was studied in the 3 groups. Results During the study period, 443 patients were included. Among them, 67, 23.7 and 9.2% were, respectively, diagnosed in groups 1, 2 and 3. Among PCa diagnosed in midline/transition zone cores, 42% were intermediate or high risk. Unfavorable disease was more frequently reported in group 1 in terms of extraprostatic extension (P = 0.001), high Gleason score (P = 0.001) and progression (P = 0.001). No signiWcant diVerence was observed between groups 2 and 3 in terms of pathological features in RP specimens and oncologic outcome. The 5-year PFS was 89.7% and not signiWcantly diVerent in patients diagnosed with a 12-core scheme compared to those diagnosed only with 21-core scheme (P = 0.332). Conclusions Our Wndings emphasize that PCa diagnosed only in a 21-core protocol is at least as aggressive as PCa detected in a 12-core scheme. This study invalidates the widespread idea sustaining that cancers diagnosed by more than 12 biopsies are less aggressive.
Introduction
Hodge's sextant prostate biopsy scheme signiWcantly increased cancer detection [1] . The systematic sextant biopsy protocol has been the standard procedure for detecting prostate cancer (PCa) for many years. Later, it has been established that the extended biopsy protocols detect more cancers [2, 3] . It is not clear whether the increased detection rate is simply due to the additional biopsies or to the location from which the cores are taken [4] . Since then, 10-, 12-, 14-, 18-and even 21-sample cores protocols have been reported [5] . In 2003, we reported a prospective study of a 21-core biopsy protocol. It showed a diagnostic yield of 42.5% without increasing morbidity [6] . To minimize false-negative results, saturation biopsy has been adopted in several centers, resulting in cancer detection rates approaching 40% [7] .
Concerns have then arisen that increasing the number of cores may lead to the detection of clinically insigniWcant, low-risk cancers [8] . Nevertheless, the concern of over-detection must be weighed against the risk of missing clinically signiWcant malignancy. In fact, saturation biopsies, which are now used as part of active surveillance protocols, have proved to provide helpful information about quantitative and qualitative histology to predict the clinical signiWcance of prostate cancer [9, 10] . Based on the systematic review of Eichler et al. [5] , the EAU guidelines recommend at least 8 cores and consider that protocols more than 12 cores are not signiWcantly more conclusive [11] .
However, the Wnal pathology and the oncologic outcomes features of the potentially missed cancers by a restricted biopsy protocol in the same patient are lacking in the current literature. Furthermore, "PCa diagnosed by extended protocols are likely to be less aggressive" is a widely spread idea [8] .
The objective of this study was to assess the pathological characteristics, on biopsy cores and Wnal pathology, and the oncologic outcomes of missed PCa by the 6¡/¡12 and detected by 21-core biopsy protocol.
Patients and methods

Patient selection
All patients referred to our department for a suspected PCa because of an abnormal DRE and/or elevated serum PSA level had an initial TRUS-guided 21-core biopsy protocol. Inclusion criteria were patients who had a Wrst positive 21-core biopsy for PCa followed by radical prostatectomy (RP) in our department between 2001 and 2009. We excluded patients treated with Finasteride, Dutasteride and preoperative hormonal therapy. Local ethics committee approval had been obtained.
TRUS biopsy protocol
The detailed protocol had already been published [6] . All participants underwent TRUS biopsies performed by one operator (ADLT).
Methods
As the protocol follows the same steps and the cores numbered and analyzed separately, patients were grouped into 3 groups as follows: PCa diagnosed after 6 cores (standard sextant biopsies; group 1) whatever the results of the additional cores; PCa diagnosed in the 6 additional posterolateral cores with negative sextant biopsies (12 cores; group 2) whatever the results from midline/transition zone cores; and PCa diagnosed only in midline/transition zone cores (21 cores; group 3) with negative 12-core biopsy scheme. If a patient has diVerent site of PCa, the patient is sorted according to the Wrst positive site. For each group, we assessed the general features of the patients and their clinical Wndings, the characteristics of the biopsy cores, the characteristics of the disease on the biopsy cores and the Wnal pathology specimens after the radical prostatectomy. The 3 groups were compared. Then, groups 1 and 2 were pooled, and their characteristics were compared with those from group 3.
Database, follow-up and statistical analysis Mean follow-up was 51.3 (median: 42, range: 1-77.2) months. Data were collected prospectively into a database and were investigated retrospectively. Pathological data were collected from biopsy cores and from the pathological prostate specimen. Quantitative data were tested using Student's t test or Mann-Whitney test as appropriate. Qualitative data were compared using a chi-square or a Fisher's test as appropriate. A double-sided P value <0.05 was considered statistically signiWcant. The 5-year progression-free survival (PFS) was estimated according to Kaplan-Meier's model, and survival curves were tested using a log-rank test. All data were analyzed using SPSS v.16.0 software (SPSS, Chicago, Illinois, USA).
Results
Among the selected patients, 443 patients completed the RP and follow-up in our department. The mean age was 63 years (range: 42-76). Table 1 shows the characteristics of the cohort. The Wnal pathology after radical prostatectomy showed a localized and a locally advanced PCa in 60.7 and 38.9%, respectively (Table 2) .
Of all, 297 (67%), 105 (23.7%) and 41 (9.2%) were diagnosed after 6 (sextant; group 1), 12 (PZ; group 2) and 21 (midline and TZ; group 3) cores, respectively. Among group 3 patients, 17 (42%) were a high or intermediate risk according to the D'Amico classiWcation and 10 (24%) Table 3 compares the PCa characteristics in function of diVerent diagnosis sites. The percentage of high Gleason score (P = 0.001), dominant Gleason grades 4-5 tumors on Wnal pathology (P = 0.001) and extraprostatic extension (P = 0.001) were signiWcantly diVerent between groups with a higher percentage of unfavorable disease in group 1. Gleason grade 4 on Wnal pathology were found in 126 (43%), 18 (17%) and 8 (20%) patients in groups 1, 2 and 3, respectively.
When the cancers diagnosed on 6-, 12-and 21-core biopsy sites were pooled (groups 1 and 2) and compared with group 3, there were more positive biopsy cores, more percentage and length of cancer on the cores (P < 0.005) in the former group. PCa diagnosed in groups 1-2 were statistically more frequently unfavorable than those diagnosed in group 3 in terms of dominant grades 4-5 (P = 0.02) and extraprostatic disease (P = 0.01). No signiWcant diVerence was observed concerning the other pathological parameters. Table 4 shows the whole comparison between groups 1-2 and group 3.
During follow-up, the 5-year PFS in groups 1, 2 and 3 patients were 78.9, 89.7 and 89.7%, respectively (Fig. 1) . The 5-year PFS in group 1 was signiWcantly poorer than those reported in groups 2 and 3 (P = 0.022). When groups 1 and 2 were pooled, diVerence did not reach signiWcance as compared to group 3 with a 5-year PFS of 81.7 and 89.7%, respectively (log rank P = 0.332).
Discussion
Biopsy protocols showed a diagnosis rate increasing with the core number [12, 13] . Since the cores were always taken in the same order and studied separately, we could use a study design we have already set in not systematically operated patients [14] . Each patient served as his own control. In this sense, we have previously shown that the biopsy core number was an important diagnostic tool in predicting the Wnal pathological features of PCa [15, 16] .
The impact of ">10-12 biopsy protocols" on PCa detection rate remains very controversial. In a previous series, it has been shown that extended biopsy scheme could improve the prognostic assessment of PCa at initial diagnosis [17, 18] . The addition of midline peripheral zone needle biopsies in the initial biopsy protocol is not supported by most of the studies [13] [14] [15] [16] [17] [18] [19] . However, a computer-based (18) 8 (8) 4 (10) modeling study showed 9.2% were diagnosed in the midline/transition zone and half of these patients had an unfavorable disease [20] .
Prognostic factors on biopsy and Wnal were signiWcantly diVerent between the 3 groups and thus according to the diagnosis site. As the 6-core biopsy protocol is not recommended anymore [11] , it appeared more relevant to us to compare the 12-and 21-core biopsy groups. Accordingly, the capsule invasion, the presence of dominant Gleason grade 4 tumor, the percentage of cancer on biopsy cores, the maximum cancer length and the number of positive cores were also diVerent in 12-and 21-core biopsy protocol.
Considering the fact that limited morbidity is associated with the 21-core biopsy protocol [6] on one hand, and the aggressiveness of the extra-diagnosed patients with the 21-core biopsy protocol on the other hand, we believe this invalidates the widespread idea sustaining that cancers diagnosed by more than 12 biopsies are less aggressive. Therefore, we believe a 21-core TRUS biopsy protocol gives a better sampling of the prostate. We have previously shown that an extended biopsy scheme (>12 cores) improved the prostate detection rate in case of repeat biopsies but also in case of Wrst set of biopsies [14, 21] . Cancers missed by an initial 12-core scheme were also more aggressive according to biopsy parameters than those missed by an initial 21-core scheme [22] . Moreover, the prediction of pT3 disease in RP specimens is improved when the diagnosis of prostate cancer is based on an extended protocol [15] . The role of biopsy core number in reducing the reclassiWcation in men eligible for active surveillance has also been emphasized [16] . Accordingly to this, we routinely perform this scheme in all patients referred for suspicion of localized PCa. However, some clinico-biological factors might be taken into account to better identify patients who will importantly beneWt from an extended procedure, such the PSA level and the prostate volume [23] .
The 5-year PFS study showed that patients diagnosed with 6 biopsies had a worse prognosis compared to those diagnosed 12-and 21-core biopsy. However, comparing patients diagnosed by 12-and 21-core biopsy did not show any diVerence. Thus, the extra-diagnosed cancers (detected only by a 21-core scheme) are at least as aggressive as those diagnosed with 12-core biopsy. We are aware this result should be interpreted with little caution due to the limited small size of group 3. A larger size of the study population and a longer follow-up should give more evidence to support our Wndings.
We would like to emphasize the limitations of our study. We used a prospective database, but data were reviewed in a retrospective manner. The population represented the majority part of PCa patients who were diagnosed, but some of them have been treated by radiotherapy or active surveillance and thus have not been included in the study because Wnal pathology was not available. Besides, the Wnal pathology shows that 30 patients had a pT4. This rose (10) concern about the management of locally advanced PCa. Combined hormonal and radiation therapy seemed to be underused. This is due to the prolonged study period. Recently, the locally advanced PCa is better deWned in the guidelines, and our practice has moved toward a less invasive approach.
Conclusion
Our Wndings emphasize PCa diagnosed only in a 21-core protocol are at least as aggressive as PCa detected in a 12-core scheme. This study invalidates the widespread idea sustaining that cancers diagnosed by more than 12 biopsies are less aggressive.
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